Condition: Oropharyngeal Squamous Cell Carcinoma · Carcinoma, Squamous Cell · Head and Neck Squamous Cell Carcinoma · Sponsor: UNC Lineberger Comprehensive Cancer Center
The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction improves when looking at HPV integration along with TRAF3 and CYLD mutations.
This description comes directly from the study's public registry record.
Lori Stravers · 919-966-4432 · lori_stravers@med.unc.edu
Wendell Yarbrough, MD · 919-843-7091 · dell@med.unc.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Active Not Recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| Trident Medical Center (HCA Healthcare ) | North Charleston, South Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04564989